Wave Life Sciences Ltd. (WVE)

NASDAQ • Healthcare

$3.18

-$0.16 (-5.1%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$3.33

Day Range$3.12 - $3.34

Avg. Volume (3M)3.1M

Market Cap$626.6M

52 Week Range

$3.04$21.73

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$2.2M100%

Gross Profitminus cost of goods$2.2M100%

Fundamentals & Financials

Revenue (TTM)

$65.3M

Net Income (TTM)

-$202.4M

EPS (TTM)

-$1.09

ROA (TTM)

-36.26%

Current Ratio

9.99

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-6.9%Q3 2025-$0.31

-6.7%Q4 2025-$0.32

-7.1%Q1 2026-$0.3

+61.8%Q2 2026-$0.13

-13.4%Q3 2026-$0.34

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -13.4%

Wave Life Sciences’ earnings missed consensus in the second fiscal quarter of 2026, reported July 30, 2026, with EPS of -$0.34 trailing the -$0.30 estimate by -$0.04. The RNA medicines developer posted GAAP net income of -roughly $69.4 million, a -37% year-over-year move from about -$50.5 million a year ago, while operating income was -about $73.8 million. Operating cash flow was negative at around -$48.3 million. On the bottom line, EPS was down -9.7% year over year from -$0.31. Looking ahead, next-period consensus calls for EPS of -$0.33 on revenue of $5.0 million.

Next report — what to expect

Wave Life Sciences Ltd. (WVE) reports next on November 9, 2026. Wall Street expects EPS of -$0.33 on revenue of $4.6 million. For trailing context, revenue fell -73.9% year over year last quarter. Wave has beaten EPS expectations in 2 of its 8 most recent quarters.

View full earnings history

About Wave Life Sciences Ltd.

Wave Life Sciences Ltd. develops RNA medicines as a Biotechnology company in healthcare, with programs aimed at genetic, metabolic, and liver disorders. Listed on NASDAQ as WVE, it recorded $42.7 million of revenue in FY2025, and its pipeline centers on disease-specific candidates for rare inherited conditions, obesity, and other liver-related disorders.

Name

Wave Life Sciences Ltd.

CEO

Paul Bolno

Website

wavelifesciences.com

Industry

Healthcare

Year Founded

2012

Employees

317

Today's Snapshot

AI-generated

The day ended with WVE 5.1% lower at 3.18, in line with a weaker sector. WVE closed within 4.6% of its 52-week low of 3.04. WVE reports earnings on 27 October.

Trading Volume

Below 10d avg (2.8M)

2.5M

vs S&P 500 Today

Strong Underperformance

-4.55%

Updated: October 23, 2026 at 20:10 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

WVE is a strong sell as of 2026-10-23 with the price at $3.18 and momentum indicators weak, including an RSI below neutral and a negative short-term momentum reading. The share price is trading under its short-, medium- and long-term moving averages, indicating broad bearish alignment, and trend strength is pronounced with ADX near 44.9 which underscores the directional momentum. Volatility is material with an ATR around 6.2 percent, and on-balance volume shows substantial selling pressure. The classic pivot lies above the current price and acts as a resistance reference. Technical takeaway: Strong Sell — strong downward trend, elevated volatility, and clear selling volume pressure.

All signals